Correlation between glomerular filtration rate, fasting glucagon like peptide 1, and response after 75 gram oral glucose loading in type 2 diabetes mellitus
Keywords:T2DM, GLP1, eGFR, fasting glucose
Background: Glucagon like peptide 1 (GLP1) is incretin hormone which possess biological effect on the kidneys. In conditions where the estimated glomerular filtration rate (eGFR) decreases or in the condition of chronic kidney disease (CKD), there is an increase in the inactive GLP1 or metabolites levels.
Objective: To prove the relationship between eGFR with fasting and response of GLP1 after oral glucose loading in type 2 diabetes mellitus (T2DM) patients.
Methods: An analytic cross sectional study on fasting and response of GLP1 after glucose loading in 60 subject with T2DM, age 35-65 years, was conducted. Each subject was obtained for fasting GLP1 and 30 minutes after 75 gram oral glucose loading. Subject were grouped based on eLFG into <60 ml/mnt/1.73m2 and ?60 ml/mnt/1.73 m2.
Result: In the group of T2DM with eGFR <60 ml/mnt/1.73m2, median fasting GLP1 was 1.43 (0.38-8.50) ng/mL, in the group of eGFR ?60 ml/mnt/1.73 m2 was 1.57 (0.46-3.69) ng/mL (p=0.124). In the group of eGFR <60 ml/mnt/1.73 m2, median GLP1 after 30 minutes was increasing to 1.78 (1.12-8.35) ng/mL, as well as in group of eGFR ?60 ml/mnt/1.73 m2 1.79 (0.65-4.22) ng/mL (p=0.250). There were no correlation between fasting and 30 minutes after oral glucose load GLP1 with eGFR (p=0.510).
Conclusion: There were no correlation between eGFR and GLP1, both fasting and 30 minutes after 75 gram oral glucose loading in T2DM. Level of GLP1 was increasing after oral glucose load in T2DM patients but not affected by stage of chronic kidney disease based on eGFR.
Perkumpulan Endokrinologi Indonesia (Perkeni). Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia. PB Perkeni. 2015; Jakarta; p.1-11.
Ghost S, Collier A. Chronic Complication. Churchill’s Pocketbook of Diabetes. 2nd. Ed. London: Elsevier. 2012, p:165-226.
Gautier JF, Choukem SP, Girard. Physiology of incretins (GIP and GLP-1) and abnormalitas in type 2 diabetes. Diabetes and Metabolism. 2008;34:s65-s72.
Nauck MA, Vardarli I, Daecon CF, Holst JJ. Secretion of glucagon-like peptide-1 in type 2 diabetes: what is up, what is down?. Diabetologia. 2011;54:10-18.
Holst JJ. The Physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409-1439.
Skov, J. Effects of GLP-1 In The Kidney. Rev Endocr Metab Disord. 2014;1-13. DOI: 10.1007/s11154-014-9287-7.
Idorn T, Knop FK, Jorgensen MB, dkk. Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. J Clin Endocrinol Metab, 2014;10:2013-2019.
DeLeon DD, Crutchlow MF, Ham JY, dkk. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int. J. Biochem. Cell Biology. 2006;38(5-6):845–859.
Vilsboll T, Krarup T, Deacon CF, dkk. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes. 2001;50:609–613.
Nugraha IBA, Saraswati MR, Suastika K. The Pattern of Fasting and Post 75 G Glucose Loading of Glucagon-Like Peptide 1 Levels in Obese and Non-Obese Subjects. Open Access Maced J Med Sci. 2019;7(3):358-362.
Ahren B. Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes. Bio Essay. 1998;20:642-651.
Schlatter P, Beglinger C, Drewe J, dkk. Glucagon-like peptide1 receptor expression in primary porcine proximal tubular cells. Regul Pept. 2007;141(1–3):120–128.
Pyke C, Knudsen LB. The Glucagon-Like Peptide-1 Receptor-or Not?. Endocrinology. 2013;154(1):4–8.
Sindhughosa,DA, Pranamartha AAGMK. The involvement of proinflammatory cytokines in diabetic nephropathy: Focus on interleukin 1 (IL-1), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-?) signaling mechanism. Bali Medical Journal. 2017;6(1):44-51.
How to Cite
Copyright (c) 2021 Jurnal Penyakit Dalam Udayana
This work is licensed under a Creative Commons Attribution 4.0 International License.
The copyright to this article is transferred to JPD (including without limitation, the right to publish the work in whole or in part in any and all forms of media, now or hereafter known) effective if and when the article is accepted for publication thus granting JPD all rights for the work so that both parties may be protected from the consequences of unauthorized use.
The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline,online) or any other reproductions of similar nature.
The authors warrant that their contribution is an original work not published elsewhere, that they have the full power to make this grant and that the article contains no matter unlawful or which invades the right to privacy or infringes any proprietary right.